Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

Namodenoson (CF102), an investigational small-molecule A3 adenosine receptor (A3AR) agonist, has demonstrated favorable ...

If these results are validated by prospective trials, it could become a valuable tool for oncologists to assess results ...

During a live event, Joshua Richter, MD, explored proactive adverse event management when using selinexor in multiple myeloma. At a live Case-Based Roundtable event during the 2025 American Society of ...

Experts weigh perioperative immunotherapy delays, rapid molecular testing, ctDNA MRD and emerging ADCs shaping early-stage lung cancer care. In this summary of a panel discussion at the 2026 TTLC ...

Enhancer hijacking emerges as a major “missing driver” mechanism in LBCL/PCN, enabling detection of non-chimeric oncogene activation such as IGL::BCL2, IGH::CCND2, and MAFA/MAFB rearrangements.

Lonial emphasizes that the EXCALIBER-RRMM trial is a test case for a new regulatory framework. The study utilizes dual primary end points to satisfy both accelerated and full approval requirements: ...

Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and compressing FDA action to 1–2 months with enhanced reviewer communication.

University of Wisconsin School of Medicine and Public Health who specializes in treating melanoma and advanced cutaneous malignancies. In an interview, Vincent Ma, MD, discussed how ctDNA levels after ...

The FDA has granted Fast Track Designation to AKY-1189 (actinium-225; 225 Ac) a potent alpha-emitting radioisotope in the ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

At the 2026 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, presented encouraging phase 1 data evaluating the ...